The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Clarke C Boyd since 2005.
The trader's CIK number is 1182504.
At the time of the last reporting, Clarke C Boyd was the Director of Novelion Therapeutics Inc.. (stock ticker symbol NVLNF).
Also see all insider trading activities at Novelion Therapeutics Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2012 | QLTI | 2,450 | $16,071 | 75,450 | $574,853 | 0 | $0 |
| 2011 | QLTI | 4,000 | $27,000 | 0 | $0 | 0 | $0 |
| 2010 | QLTI | 3,000 | $17,250 | 0 | $0 | 0 | $0 |
| 2009 | QLTI | 29,000 | $61,986 | 0 | $0 | 0 | $0 |
| 2008 | QLTI | 10,000 | $24,670 | 0 | $0 | 0 | $0 |
| 2007 | QLTI | 24,000 | $137,079 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2005 | NTEC | 10,000 | $27,140 | 0 | $0 | 0 | $0 |
1. Novelion Therapeutics Inc. (QLTI)
2. Neose Technologies Inc (NTEC)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2012-07-09 | QLTI | Sale | 75,450 | 7.62 | 574,853 |
| 2012-05-15 | QLTI | Buy | 2,450 | 6.56 | 16,071 |
| 2011-06-17 | QLTI | Buy | 4,000 | 6.75 | 27,000 |
| 2010-08-02 | QLTI | Buy | 3,000 | 5.75 | 17,250 |
| 2009-11-03 | QLTI | Buy | 5,000 | 3.39 | 16,950 |
| 2009-05-12 | QLTI | Buy | 10,000 | 2.21 | 22,100 |
| 2009-03-04 | QLTI | Buy | 10,000 | 1.61 | 16,060 |
| 2009-02-23 | QLTI | Buy | 4,000 | 1.72 | 6,876 |
| 2008-10-30 | QLTI | Buy | 10,000 | 2.47 | 24,670 |
| 2007-10-26 | QLTI | Buy | 14,000 | 4.52 | 63,279 |
| 2007-05-07 | QLTI | Buy | 10,000 | 7.38 | 73,800 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2005-05-05 | NTEC | Buy | 10,000 | 2.71 | 27,140 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Clarke C Boyd (Director of Novelion Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.